A	O
phase	B-study_type
II	I-study_type
study	I-study_type
of	O
ibrutinib	B-arm_description
in	O
combination	B-arm_description
with	I-arm_description
rituximab	I-arm_description
-	I-arm_description
cyclophosphamide	I-arm_description
-	I-arm_description
doxorubicin	I-arm_description
hydrochloride	I-arm_description
-	I-arm_description
vincristine	I-arm_description
sulfate	I-arm_description
-	I-arm_description
prednisone	I-arm_description
therapy	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
positive	O
,	O
diffuse	O
large	O
B	O
cell	O
lymphoma	O
(	O
54179060LYM2003	O
:	O
IVORY	O
study	O
)	O
:	O
results	O
of	O
the	O
final	O
analysis	O
A	O
phase	B-study_type
II	I-study_type
study	I-study_type
of	O
ibrutinib	B-arm_description
in	O
combination	B-arm_description
with	I-arm_description
rituximab	I-arm_description
-	I-arm_description
cyclophosphamide	I-arm_description
-	I-arm_description
doxorubicin	I-arm_description
hydrochloride	I-arm_description
-	I-arm_description
vincristine	I-arm_description
sulfate	I-arm_description
-	I-arm_description
prednisone	I-arm_description
therapy	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
positive	O
,	O
diffuse	O
large	O
B	O
cell	O
lymphoma	O
(	O
54179060LYM2003	O
:	O
IVORY	O
study	O
)	O
:	O
results	O
of	O
the	O
final	O
analysis	O
24	O
April	O
2020	O
24	O
April	O
2020	O
SangEunYoon	B-authors

A	O
phase	B-study_type
II	I-study_type
study	I-study_type
of	O
ibrutinib	B-arm_description
in	O
combination	O
with	O
rituximab	B-arm_description
-	I-arm_description
cyclophosphamide	I-arm_description
-	I-arm_description
doxorubicin	I-arm_description
hydrochloride	I-arm_description
-	I-arm_description
vincristine	I-arm_description
sulfate	I-arm_description
-	I-arm_description
prednisone	I-arm_description
therapy	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
positive	O
,	O
diffuse	O
large	O
B	O
cell	O
lymphoma	O
(	O
54179060LYM2003	O
:	O
IVORY	O
study	O
)	O
:	O
results	O
of	O
the	O
final	O
analysis	O
24	O
April	O
2020	O

A	O
phase	B-study_type
II	I-study_type
study	I-study_type
of	O
ibrutinib	B-arm_description
in	O
combination	O
with	O
rituximab	B-arm_description
-	I-arm_description
cyclophosphamide	I-arm_description
-	I-arm_description
doxorubicin	I-arm_description
hydrochloride	I-arm_description
-	I-arm_description
vincristine	I-arm_description
sulfate	I-arm_description
-	I-arm_description
prednisone	I-arm_description
therapy	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
positive	O
,	O
diffuse	O
large	O
B	O
cell	O
lymphoma	O
(	O
54179060LYM2003	O
:	O
IVORY	O
study	O
)	O
:	O
results	O
of	O
the	O
final	O
analysis	O
24	O
April	O
2020	O

A	O
phase	B-study_type
II	I-study_type
study	I-study_type
of	O
ibrutinib	B-arm_description
in	O
combination	B-arm_description
with	I-arm_description
rituximab	I-arm_description
-	I-arm_description
cyclophosphamide	I-arm_description
-	I-arm_description
doxorubicin	I-arm_description
hydrochloride	I-arm_description
-	I-arm_description
vincristine	I-arm_description
sulfate	I-arm_description
-	I-arm_description
prednisone	I-arm_description
therapy	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
positive	O
,	O
diffuse	O
large	O
B	O
cell	O
lymphoma	O
(	O
54179060LYM2003	O
:	O
IVORY	O
study	O
)	O
:	O
results	O
of	O
the	O
final	O
analysis	O
SangEunYoon	B-authors

South	O
Korea	O
Division	O
of	O
Hematology	O
and	O
Oncology	O
Department	O
of	O
Medicine	O
Samsung	O
Medical	O
Center	O
Sungkyunkwan	O
University	O
School	O
of	O
Medicine	O
81	O
,	O
Irwon	O
-	O
ro	O
,	O
Gangnam	O
-	O
gu	O
06351	O
Seoul	O

South	O
Korea	O
81	O
,	O
Irwon	O
-	O
ro	O
,	O
Gangnam	O
-	O
gu	O
06351	O
Seoul	O
South	O
Korea	O
Division	O
of	O
Hematology	O
and	O
Oncology	O
Department	O
of	O
Medicine	O
Samsung	O
Medical	O
Center	O

South	O
Korea	O
Division	O
of	O
Hematology	O
and	O
Oncology	O
Department	O
of	O
Medicine	O
Samsung	O
Medical	O
Center	O
Sungkyunkwan	O
University	O
School	O
of	O
Medicine	O
81	O
,	O
Irwon	O
-	O
ro	O
,	O
Gangnam	O
-	O
gu	O
06351	O
Seoul	O

South	O
Korea	O
Division	O
of	O
Hematology	O
and	O
Oncology	O
Department	O
of	O
Medicine	O
Samsung	O
Medical	O
Center	O
Sungkyunkwan	O
University	O
School	O
of	O
Medicine	O
81	O
,	O
Irwon	O
-	O
ro	O
,	O
Gangnam	O
-	O
gu	O
06351	O
Seoul	O

South	O
Korea	O
81	O
,	O
Irwon	O
-	O
ro	O
,	O
Gangnam	O
-	O
gu	O
06351	O
Seoul	O
South	O
Korea	O
Division	O
of	O
Hematology	O
and	O
Oncology	O
Department	O
of	O
Medicine	O
Samsung	O
Medical	O
Center	O

South	O
Korea	O
Division	O
of	O
Hematology	O
and	O
Oncology	O
Department	O
of	O
Medicine	O
Samsung	O
Medical	O
Center	O
Sungkyunkwan	O
University	O
School	O
of	O
Medicine	O
81	O
,	O
Irwon	O
-	O
ro	O
,	O
Gangnam	O
-	O
gu	O
06351	O
Seoul	O

South	O
Korea	O
81	O
,	O
Irwon	O
-	O
ro	O
,	O
Gangnam	O
-	O
gu	O
06351	O
Seoul	O
South	O
Korea	O
&	O
Dok	O
&	O
Dok	O
&	O
Dok	B-authors
HyunYoon	I-authors
Department	O
of	O
Oncology	O
Asan	O
Medical	O
Center	O

South	O
Korea	O
Division	O
of	O
Hematology	O
and	O
Oncology	O
Department	O
of	O
Medicine	O
Samsung	O
Medical	O
Center	O
Sungkyunkwan	O
University	O
School	O
of	O
Medicine	O
81	O
,	O
Irwon	O
-	O
ro	O
,	O
Gangnam	O
-	O
gu	O
06351	O
Seoul	O

South	O
Korea	O
Division	O
of	O
Hematology	O
and	O
Oncology	O
Department	O
of	O
Medicine	O
Samsung	O
Medical	O
Center	O
Sungkyunkwan	O
University	O
School	O
of	O
Medicine	O
81	O
,	O
Irwon	O
-	O
ro	O
,	O
Gangnam	O
-	O
gu	O
06351	O
Seoul	O

South	O
Korea	O
81	O
,	O
Irwon	O
-	O
ro	O
,	O
Gangnam	O
-	O
gu	O
06351	O
Seoul	O
South	O
Korea	O
A	O
phase	B-study_type
II	I-study_type
study	I-study_type
of	O
ibrutinib	B-arm_description
in	O
combination	O
with	O
rituximab	B-arm_description
-	I-arm_description
cyclophosphamide	I-arm_description
-	I-arm_description
doxorubicin	I-arm_description
hydrochloride	I-arm_description
-	I-arm_description
vincristine	I-arm_description
sulfate	I-arm_description
-	I-arm_description
prednisone	I-arm_description
therapy	O
in	O
Epstein	O
-	O
Barr	O
virus	O
-	O
positive	O
,	O
diffuse	O
large	O
B	O
cell	O
lymphoma	O
(	O
54179060LYM2003	O
:	O
IVORY	O
study	O
)	O
:	O
results	O
of	O
the	O
final	O
analysis	O
24	O
April	O
2020	O
24	O
April	O
2020	O
24	O
April	O
2020	O
10.1007	O
/	O
s00277	O
-	O
020	O
-	O
04005	O
-	O
6	O
Received	O
:	O
31	O
October	O
2019	O
/	O
Accepted	O
:	O
12	O
March	O
2020	O
#	O
The	O
Author(s	O
)	O
2020	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV)-positive	O
,	O
diffuse	O
large	O
B	O
cell	O
lymphoma	O
(	O
DLBCL	O
)	O
is	O
an	O
EBV	O
-	O
positive	O
,	O
monoclonal	O
,	O
large	O
B	O
cell	O
lymphoproliferative	O
disorder	O
mainly	O
seen	O
in	O
individuals	O
older	O
than	O
50	O
years	O
of	O
age	O
[	O
1,2	O
]	O
.	O
Previous	O
studies	O
have	O
shown	O
that	O
EBV	O
-	O
positive	O
DLBCL	O
is	O
mainly	O
correlated	O
with	O
high	O
-	O
intermediate	O
/	O
high	O
International	O
Prognostic	O
Index	O
(	O
IPI	O
)	O
scores	O
,	O
advanced	O
disease	O
stage	O
(	O
III	O
/	O
IV	O
)	O
at	O
diagnosis	O
,	O
and	O
inferior	O
outcomes	O
in	O
comparison	O
with	O
EBV	O
-	O
negative	O
DLBCL	O
[	O
3,4	O
]	O
.	O

EBV	O
-	O
infected	O
cells	O
encode	O
eight	O
EBV	O
-	O
encoded	O
latent	O
genes	O
consisting	O
of	O
six	O
EBV	O
-	O
encoded	O
nuclear	O
antigens	O
(	O
EBNAs	O
)	O
and	O
two	O
latent	O
membrane	O
proteins	O
(	O
LMP1	O
and	O
LMP2	O
)	O
[	O
5	O
]	O
.	O
LMP1	O
and	O
LMP2	O
in	O
particular	O
behave	O
like	O
B	O
cell	O
receptor	O
(	O
BCR)mediated	O
Akt	O
,	O
which	O
is	O
dependent	O
upon	O
spleen	O
tyrosine	O
kinase	O
and	O
Bruton	O
's	O
tyrosine	O
kinase	O
(	O
BTK	O
)	O
.	O
These	O
tyrosine	O
kinases	O
contribute	O
to	O
enhanced	O
cellular	O
proliferation	O
and	O
survival	O
signaling	O
such	O
as	O
the	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
κB	O
)	O
and	O
phosphoinositide	O
3-kinase	O
(	O
PI3K	O
/	O
Akt	O
)	O
pathways	O
[	O
6	O
]	O
.	O
In	O
our	O
experiment	O
,	O
we	O
transfected	O
vector	O
-	O
encoding	O
LMP1	O
or	O
LMP1_delCTAR1(C	O
-	O
terminal	O
-	O
activating	O
region	O
1	O
)	O
and	O
LMP1_delCTAR2	O
into	O
a	O
DLBCL	O
cell	O
line	O
and	O
observed	O
the	O
BCR	O
signaling	O
pathway	O
(	O
Supplementary	O
Materials	O
and	O
methods	O
)	O
.	O
As	O
a	O
result	O
,	O
the	O
BTK	O
signaling	O
pathway	O
was	O
activated	O
when	O
LMP1	O
was	O
expressed	O
.	O
It	O
was	O
also	O
confirmed	O
that	O
the	O
CTAR1	O
of	O
LMP1	O
was	O
an	O
important	O
domain	O
for	O
BTK	O
activation	O
.	O
In	O
addition	O
,	O
cell	O
viability	O
was	O
decreased	O
when	O
the	O
BTK	O
inhibitor	O
(	O
ibrutinib	O
)	O
was	O
treated	O
with	O
LMP1-expressing	O
cells	O
(	O
Supplementary	O
Fig	O
.	O
S1	O
)	O
.	O
Based	O
on	O
previous	O
studies	O
that	O
proved	O
the	O
efficacy	O
of	O
rituximab	O
-	O
cyclophosphamidedoxorubicin	O
hydrochloride	O
-	O
vincristine	O
sulfate	O
-	O
prednisone	O
(	O
RCHOP	O
)	O
therapy	O
combined	O
with	O
ibrutinib	O
(	O
I	O
-	O
RCHOP	O
)	O
,	O
we	O
designed	O
this	O
study	O
to	O
boost	O
the	O
anti	O
-	O
tumor	O
effect	O
of	O
EBVpositive	O
DLBCL	O
[	O
7,8	O
]	O
.	O
Here	O
,	O
we	O
report	O
the	O
results	O
of	O
an	O
open	B-study_type
-	I-study_type
label	I-study_type
,	I-study_type
multicenter	I-study_type
phase	I-study_type
II	I-study_type
study	I-study_type
that	O
investigated	O
the	O
combination	O
ibrutinib	B-arm_description
and	O
RCHOP	B-arm_description
for	O
EBV	O
-	O
positive	O
DLBCL	O
using	O
a	O
matched	O
case	O
-	O
control	O
study	O
.	O

This	O
study	O
was	O
an	O
open	B-study_type
-	I-study_type
label	I-study_type
,	I-study_type
single	I-study_type
-	I-study_type
arm	I-study_type
,	I-study_type
prospective	I-study_type
multicenter	I-study_type
clinical	I-study_type
trial	I-study_type
for	O
evaluating	O
the	O
efficacy	O
and	O
toxicity	O
of	O
I	O
-	O
RCHOP	B-arm_description
in	O
subjects	O
with	O
newly	O
diagnosed	O
,	O
chemotherapy	O
-	O
naïve	O
,	O
EBV	O
-	O
positive	O
DLBCL	O
.	O
We	O
defined	O
EBV	O
positivity	O
as	O
a	O
finding	O
of	O
20	O
%	O
or	O
more	O
of	O
EBV	O
-	O
encoded	O
RNA	O
in	O
situ	O
hybridization	O
-	O
positive	O
tumor	O
cells	O
among	O
total	O
tumor	O
cells	O
during	O
pathology	O
evaluation	O
[	O
2	O
]	O
.	O
Ibrutinib	B-arm_description
(	O
560	B-arm_dosage
mg/	I-arm_dosage
day	I-arm_dosage
)	O
was	O
administrated	O
orally	B-arm_dosage
and	O
RCHOP	B-arm_description
(	O
rituximab	B-arm_description
375	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
,	I-arm_dosage
cyclophosphamide	B-arm_description
750	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
,	I-arm_dosage
doxorubicin	B-arm_description
50	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
,	I-arm_dosage
vincristine	B-arm_description
1.4	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
(	I-arm_dosage
maximum	I-arm_dosage
total	I-arm_dosage
of	I-arm_dosage
2	I-arm_dosage
mg	I-arm_dosage
)	I-arm_dosage
on	I-arm_dosage
day	I-arm_dosage
1	I-arm_dosage
and	I-arm_dosage
oral	I-arm_dosage
prednisone	B-arm_description
100	I-arm_dosage
mg	I-arm_dosage
on	I-arm_dosage
days	I-arm_dosage
1	I-arm_dosage
-	I-arm_dosage
5	I-arm_dosage
)	O
therapy	O
was	O
administered	O
intravenously	B-arm_dosage
every	I-arm_dosage
21	I-arm_dosage
days	I-arm_dosage
,	O
respectively	O
,	O
until	O
the	O
end	O
of	O
6	B-arm_dosage
cycles	I-arm_dosage
or	O
progression	O
or	O
unacceptable	O
toxicity	O
were	O
observed	O
.	O

Patients	O
had	O
to	O
fulfill	O
the	O
following	O
criteria	O
to	O
be	O
included	O
in	O
this	O
research	O
:	O
(	O
1	O
)	O
histologically	O
confirmed	O
EBV	O
-	O
positive	O
DLBCL	O
without	O
central	O
nervous	O
system	O
involvement	O
;	O
(	O
2	O
)	O
aged	O
19	O
years	O
or	O
older	O
;	O
(	O
3	O
)	O
no	O
previous	O
treatment	O
for	O
DLBCL	O
,	O
although	O
we	O
allowed	O
the	O
usage	O
of	O
prednisolone	B-arm_description
100	O
mg	O
or	O
equivalent	O
dosage	O
of	O
any	O
type	O
of	O
steroid	O
(	O
for	O
a	O
maximum	O
of	O
7	O
days	O
)	O
and	O
radiation	O
for	O
reducing	O
symptoms	O
related	O
with	O
mass	O
effect	O
;	O
(	O
4	O
)	O
one	O
or	O
more	O
measurable	O
lesions	O
;	O
(	O
5	O
)	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
of	O
0	O
to	O
2	O
;	O
and	O
(	O
6	O
)	O
adequate	O
organ	O
function	O
.	O
The	O
exclusion	O
criteria	O
included	O
any	O
life	O
-	O
threatening	O
illness	O
,	O
medical	O
condition	O
,	O
or	O
organ	O
system	O
dysfunction	O
that	O
could	O
compromise	O
the	O
subject	O
's	O
safety	O
,	O
according	O
to	O
the	O
investigator	O
's	O
opinion	O
.	O
Written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
patient	O
prior	O
to	O
study	O
enrollment	O
.	O
This	O
study	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
of	O
each	O
institution	O
and	O
conducted	O
in	O
accordance	O
with	O
the	O
tenets	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O
This	O
trial	O
was	O
registered	O
at	O
www.ClinicalTrials.gov	O
as	O
NCT02670616	O
.	O

In	O
addition	O
,	O
we	O
organized	O
a	O
case	O
-	O
control	O
study	O
to	O
figure	O
out	O
the	O
superiority	O
(	O
e.g.	O
,	O
overall	O
response	O
rate	O
,	O
toxicity	O
)	O
of	O
RCHOP	B-arm_description
(	O
control	O
)	O
and	O
I	O
-	O
RCHOP	B-arm_description
(	O
case	O
)	O
in	O
EBV	O
-	O
positive	O
DLBCL	O
.	O
To	O
serve	O
as	O
matched	O
controls	O
,	O
we	O
selected	O
EBV	O
-	O
positive	O
DLBCL	O
patients	O
who	O
received	O
only	O
RCHOP	B-arm_description
chemotherapy	O
from	O
2006	O
to	O
2018	O
as	O
part	O
of	O
Samsung	O
Medical	O
Center	O
's	O
prospective	O
lymphoma	O
registry	O
(	O
Fig	O
.	O
1b	O
)	O
.	O
Especially	O
,	O
we	O
employed	O
strict	O
matching	O
categories	O
,	O
which	O
were	O
age	O
,	O
ECOG	O
performance	O
status	O
,	O
IPI	O
score	O
,	O
and	O
Ann	O
Arbor	O
stage	O
(	O
Supplementary	O
Table	O
S1	O
)	O
.	O

The	O
primary	O
endpoint	O
of	O
this	O
research	O
was	O
the	O
objective	O
response	O
rate	O
(	O
ORR	O
)	O
based	O
on	O
the	O
proportion	O
of	O
complete	O
response	O
(	O
CR	O
)	O
and	O
partial	O
response	O
(	O
PR	O
)	O
.	O
Secondary	O
endpoints	O
included	O
toxicity	O
,	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
(	O
PFS	B-arm_efficacy_metric
)	O
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
Adverse	O
events	O
(	O
AEs	O
)	O
were	O
assessed	O
according	O
to	O
the	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
version	O
4.0	O
.	O

In	O
study	O
participants	O
,	O
complete	O
blood	O
count	O
,	O
organ	O
function	O
(	O
i.e.	O
,	O
creatinine	O
,	O
aspartate	O
transaminase	O
,	O
alanine	O
transaminase	O
)	O
,	O
EBV	O
DNA	O
titer	O
,	O
electrocardiogram	O
(	O
ECG	O
)	O
,	O
transthoracic	O
echocardiogram	O
(	O
TTE	O
)	O
,	O
and	O
measurable	O
lesions	O
were	O
assessed	O
with	O
computed	O
tomography	O
(	O
CT	O
)	O
scans	O
of	O
the	O
neck	O
,	O
chest	O
,	O
and	O
abdominal	O
pelvis	O
or	O
18	O
F	O
-	O
fluorodeoxyglucose	O
positronemission	O
tomography	O
(	O
PET)/CT	O
scans	O
at	O
before	O
enrollment	O
,	O
during	O
treatment	O
,	O
and	O
at	O
the	O
end	O
of	O
treatment	O
.	O
We	O
assessed	O
response	O
according	O
to	O
the	O
Lugano	O
response	O
criteria	O
for	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
[	O
9	O
]	O
.	O

The	O
aforementioned	O
previous	O
study	O
with	O
EBV	O
-	O
positive	O
DLBCL	O
revealed	O
a	O
50	O
%	O
complete	O
response	O
rate	O
was	O
achieved	O
by	O
RCHOP	B-arm_description
without	O
the	O
use	O
of	O
ibrutinib	B-arm_description
[	O
1	O
]	O
.	O
Separately	O
,	O
the	O
phase	O
I	O
clinical	O
trial	O
with	O
DLBCL	O
patients	O
who	O
received	O
ibrutinib	B-arm_description
(	O
560	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
day	I-arm_dosage
)	O
in	O
conjunction	O
with	O
RCHOP	B-arm_description
presented	O
a	O
95	O
%	O
overall	O
response	O
rate	O
,	O
including	O
both	O
cases	O
of	O
CR	O
and	O
PR	O
[	O
10	O
]	O
.	O
From	O
these	O
results	O
,	O
we	O
hypothesized	O
that	O
the	O
complete	O
response	O
rate	O
of	O
EBV	O
-	O
positive	O
DLBCL	O
might	O
be	O
up	O
to	O
80	O
%	O
when	O
ibrutinib	B-arm_description
and	O
RCHOP	B-arm_description
were	O
combined	O
.	O
Thus	O
,	O
if	O
we	O
could	O
achieve	O
complete	O
response	O
in	O
14	O
out	O
of	O
21	O
patients	O
,	O
we	O
could	O
rule	O
that	O
our	O
new	O
regimen	O
might	O
be	O
effective	O
for	O
this	O
disorder	O
and	O
likely	O
could	O
start	O
further	O
investigations	O
such	O
as	O
phase	O
I	O
/	O
II	O
trials	O
(	O
P0	O
=	O
50	O
%	O
,	O
one	O
-	O
sided	O
alpha	O
=	O
5	O
%	O
,	O
P1	O
=	O
80	O
%	O
,	O
statistical	O
power	O
=	O
90	O
%	O
)	O
[	O
11	O
]	O
.	O
Considering	O
a	O
10	O
%	O
rate	O
of	O
interruption	O
,	O
a	O
total	O
of	O
24	O
patients	O
were	O
included	O
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
the	O
IBM	O
PASW	O
version	O
24.0	O
software	O
program	O
(	O
SPSS	O
Inc.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O
In	O
the	O
scheme	O
to	O
demonstrate	O
the	O
superiority	O
of	O
I	O
-	O
RCHOP	B-arm_description
and	O
RCHOP	B-arm_description
,	O
descriptive	O
statistics	O
was	O
reported	O
as	O
proportions	O
and	O
medians	O
,	O
and	O
intergroup	O
comparisons	O
were	O
achieved	O
using	O
Fisher	O
's	O
exact	O
test	O
for	O
categorical	O
variables	O
.	O

In	O
addition	O
,	O
survival	O
curves	O
were	O
achieved	O
using	O
the	O
Kaplan	O
-	O
Meier	O
method	O
,	O
and	O
the	O
comparison	O
of	O
survival	O
rates	O
was	O
calculated	O
with	O
the	O
log	O
-	O
rank	O
test	O
.	O
Univariate	O
and	O
multivariate	O
analyses	O
for	O
the	O
assessment	O
of	O
predictive	O
values	O
of	O
I	O
-	O
RCHOP	B-arm_description
were	O
completed	O
using	O
Cox	O
's	O
regression	O
model	O
.	O
A	O
two	O
-	O
sided	O
p	O
value	O
of	O
less	O
than	O
0.05	O
was	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O

Between	O
September	O
2016	O
and	O
August	O
2019	O
,	O
24	O
patients	O
were	O
enrolled	O
from	O
10	O
institutes	O
.	O
The	O
cutoff	O
date	O
for	O
analysis	O
was	O
March	O
2019	O
,	O
and	O
the	O
median	O
follow	O
-	O
up	O
period	O
was	O
7.9	O
months	O
,	O
with	O
six	O
death	O
events	O
(	O
25	O
%	O
)	O
.	O
Sixteen	O
patients	O
(	O
67	O
%	O
)	O
finished	O
6	O
cycles	O
of	O
chemotherapy	O
.	O
In	O
the	O
48	O
patients	O
who	O
were	O
confirmed	O
to	O
have	O
EBV	O
-	O
positive	O
DLBCL	O
at	O
Samsung	O
Medical	O
Center	O
for	O
the	O
purpose	O
of	O
the	O
matched	O
case	O
-	O
control	O
study	O
,	O
baseline	O
clinical	O
characteristics	O
were	O
balanced	O
comparatively	O
among	O
both	O
the	O
I	O
-	O
RCHOP	B-arm_description
(	O
n	O
=	O
24	O
)	O
and	O
RCHOP	B-arm_description
(	O
n	O
=	O
24	O
)	O
groups	O
(	O
Table	O
1	O
)	O
.	O
The	O
median	O
ages	O
were	O
58	O
years	O
(	O
range	O
,	O

The	O
ORR	O
of	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
was	O
66.7	O
%	O
(	O
n	O
=	O
16	O
)	O
.	O
The	O
most	O
common	O
cause	O
for	O
treatment	O
interruption	O
was	O
AEs	O
(	O
n	O
=	O
5	O
;	O
21	O
%	O
)	O
,	O
followed	O
by	O
disease	O
progression	O
(	O
n	O
=	O
3	O
;	O
12.5	O
%	O
)	O
(	O
Fig	O
.	O
1a	O
)	O
.	O
Among	O
the	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
patients	O
,	O
who	O
displayed	O
a	O
66.7	O
%	O
ORR	O
,	O
those	O
aged	O
younger	O
than	O
65	O
years	O
(	O
87.5	O
%	O
)	O
achieved	O
a	O
superior	O
ORR	O
than	O
did	O
those	O
older	O
than	O
65	O
years	O
(	O
25.0	O
%	O
;	O
p	O
=	O
0.01	O
;	O
Table	O
2	O
)	O
.	O
When	O
comparing	O
with	O
findings	O
of	O
the	O
matched	O
case	O
-	O
control	O
group	O
,	O
for	O
all	O
patients	O
aged	O
younger	O
than	O
65	O
years	O
,	O
though	O
there	O
was	O
a	O
higher	O
CR	O
rate	O
for	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
(	O
87.3	O
%	O
vs.	O
68.8	O
%	O
)	O
,	O
the	O
ORR	O
(	O
87.5	O
%	O
vs.	O
75.0	O
%	O
;	O
p	O
=	O
0.69	O
)	O
between	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
and	O
RCHOP	B-arm_description
did	O
not	O
show	O
a	O
significant	O
difference	O
.	O
In	O
the	O
patients	O
older	O
than	O
65	O
years	O
of	O
age	O
,	O
50	O
%	O
of	O
patients	O
in	O
the	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
group	O
dropped	O
out	O
previously	O
due	O
to	O
unacceptable	O
toxicities	O
before	O
the	O
end	O
of	O
the	O
treatment	O
period	O
;	O
thus	O
,	O
the	O
response	O
rate	O
was	O
superior	O
in	O
patients	O
who	O
received	O
RCHOP	B-arm_description
(	O
50.0	O
%	O
vs.	O
25.0	O
%	O
;	O
p	O
=	O
0.81	O
;	O
Table	O
3	O
)	O
.	O

Across	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
and	O
RCHOP	B-arm_description
,	O
most	O
patients	O
older	O
than	O
65	O
years	O
of	O
age	O
in	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
group	O
could	O
not	O
complete	O
6	O
cycles	O
of	O
chemotherapy	O
(	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
,	O
87.5	O
%	O
vs.	O
25.0	O
%	O
;	O

RCHOP	B-arm_description
81.3	O
%	O
vs.	O
50.0	O
%	O
)	O
due	O
to	O
grades	O
3/4	O
AEs	O
(	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
,	O
40.0	O
%	O
vs.	O
82.5	O
%	O
;	O
RCHOP	B-arm_description
,	O
75.0	O
%	O
vs.	O
75.0	O
%	O
)	O
.	O
In	O
addition	O
,	O
there	O
were	O
not	O
any	O
EBV	O
reactivation	O
case	O
.	O
In	O
the	O
patients	O
who	O
received	O
I	O
-	O
RCHOP	O
,	O
there	O
were	O
four	O
treatmentrelated	O
deaths	O
mainly	O
associated	O
with	O
the	O
unusual	O
infection	O
without	O
grades	O
3/4	O
neutropenia	O
(	O
Table	O
4	O
)	O
.	O
For	O
example	O
,	O
a	O
patient	O
younger	O
than	O
65	O
years	O
died	O
due	O
to	O
a	O
disseminated	O
brain	O
abscess	O
caused	O
by	O
bacteria	O
(	O
confirmed	O
by	O
brain	O
magnetic	O
resonance	O
imaging	O
)	O
,	O
while	O
three	O
patients	O
older	O
than	O
65	O
years	O
of	O
age	O
died	O
due	O
to	O
bacterial	O
meningitis	O
(	O
diagnosed	O
by	O
cerebrospinal	O
fluid	O
analysis	O
,	O
brain	O
magnetic	O
resonance	O
imaging	O
)	O
,	O
sepsis	O
combined	O
with	O
pneumonia	O
caused	O
by	O
streptococci	O
hemolytic	O
species	O
,	O
and	O
invasive	O
pulmonary	O
aspergillosis	O
,	O
respectively	O
.	O

Median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
(	O
20.6	B-arm_efficacy_results
months	I-arm_efficacy_results
,	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
non	I-arm_efficacy_results
-	I-arm_efficacy_results
evaluable	I-arm_efficacy_results
vs.	O
35.3	B-arm_efficacy_results
months	I-arm_efficacy_results
,	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
0.0	I-arm_efficacy_results
-	I-arm_efficacy_results
86.9	I-arm_efficacy_results
;	I-arm_efficacy_results
p	I-arm_efficacy_results
=	I-arm_efficacy_results
0.46	I-arm_efficacy_results
)	O
and	O
median	O
OS	O
(	O
20.9	O
months	O
,	O
95	O
%	O
CI	O
0.6	O
-	O
41.2	O
vs.	O
48.1	O
months	O
,	O
95	O
%	O
CI	O
NR	O
;	O
p	O
=	O
0.72	O
)	O
according	O
to	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
and	O
RCHOP	B-arm_description
were	O
not	O
significantly	O
different	O
(	O
Fig	O
.	O
2a	O
and	O
b	O
)	O
.	O
Based	O
on	O
the	O
one	O
-	O
year	O
survival	O
analysis	O
,	O
one	O
-	O
year	O
OS	O
(	O
33.3	O
%	O
vs.	O
58.3	O
%	O
;	O
p	O
=	O
0.15	O
)	O
and	O
PFS	B-arm_efficacy_metric
(	O
29.2	B-arm_efficacy_results
%	I-arm_efficacy_results
vs.	O
36.8	B-arm_efficacy_results
%	I-arm_efficacy_results
,	I-arm_efficacy_results
p	I-arm_efficacy_results
=	I-arm_efficacy_results
0.24	I-arm_efficacy_results
)	O
were	O
not	O
correlated	O
with	O
more	O
favorable	O
outcomes	O
in	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
than	O
in	O
RCHOP	B-arm_description
among	O
all	O
patients	O
.	O
In	O
line	O
with	O
age	O
-	O
based	O
case	O
-	O
control	O
comparisons	O
,	O
in	O
patients	O
aged	O
younger	O
than	O
65	O
years	O
,	O
the	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
(	O
NR	B-arm_efficacy_results
vs.	O
92.2	B-arm_efficacy_results
months	I-arm_efficacy_results
,	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
9.8	I-arm_efficacy_results
-	I-arm_efficacy_results
176.0	I-arm_efficacy_results
;	I-arm_efficacy_results
p	I-arm_efficacy_results
=	I-arm_efficacy_results
0.68	I-arm_efficacy_results
)	O
and	O
OS	O
(	O
NR	O
vs.	O
NR	O
;	O
p	O
=	O
0.45	O
)	O
showed	O
a	O
superior	O
tendency	O
in	O
the	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
group	O
(	O
Fig	O
.	O
2c	O
and	O
d	O
)	O
.	O
In	O
patients	O
aged	O
older	O
than	O
65	O
years	O
,	O
the	O
survival	O
benefit	O
was	O
lower	O
in	O
the	O
I	O
-	O
RCHOP	O
group	O
because	O
of	O
the	O
large	O
number	O
of	O
patients	O
terminated	O
during	O
the	O
initial	O
treatment	O
(	O
Figs	O
.	O
2e	O
,	O
f	O
,	O
and	O
3	O
)	O
.	O

Univariate	O
and	O
multivariate	O
analyses	O
were	O
performed	O
to	O
determine	O
the	O
predictive	O
factors	O
of	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
from	O
the	O
Cox	O
proportional	O
hazards	O
model	O
analysis	O
of	O
PFS	B-arm_efficacy_metric
according	O
to	O
baseline	O
characteristics	O
.	O
The	O
results	O
of	O
univariate	O
analysis	O
revealed	O
worse	O
outcomes	O
in	O
those	O
aged	O
older	O
than	O
65	O
years	O
(	O
HR	B-arm_efficacy_results
5.54	I-arm_efficacy_results
,	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
1.37	I-arm_efficacy_results
-	I-arm_efficacy_results
22.38	I-arm_efficacy_results
;	I-arm_efficacy_results
p	I-arm_efficacy_results
=	I-arm_efficacy_results
0.02	I-arm_efficacy_results
)	I-arm_efficacy_results
and	O
favorable	O
outcomes	O
in	O
those	O
who	O
finished	O
6	O
cycles	O
(	B-arm_efficacy_results
HR	I-arm_efficacy_results
,	I-arm_efficacy_results
0.03	I-arm_efficacy_results
;	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
0.03	I-arm_efficacy_results
-	I-arm_efficacy_results
0.21	I-arm_efficacy_results
;	I-arm_efficacy_results
p	I-arm_efficacy_results
=	I-arm_efficacy_results
0.00	I-arm_efficacy_results
)	I-arm_efficacy_results
.	O
In	O
multivariate	O
analysis	O
,	O
having	O
completed	O
6	O
cycles	O
of	O
chemotherapy	O
was	O
only	O
demonstrated	O
to	O
be	O
an	O
independent	O
prognostic	O
factor	O
for	O
I	B-arm_description
-	I-arm_description
RCHOP	I-arm_description
(	O
HR	O
,	O
0.02	O
.	O
95	O
%	O
CI	O
,	O
0.00	O
-	O
0.21	O
;	O
p	O
=	O
0.00	O
;	O
Table	O
5	O
)	O
.	O